A Twelve-Month, Randomized, Double-Masked, Multicenter, Phase III, Two-Arm Study Comparing the Efficacy and Safety of Brolucizumab 6 mg Versus Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration
收藏DataCite Commons2026-03-27 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012919/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
To compare brolucizumab to aflibercept in Chinese patients with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)
提供机构：
Vivli
创建时间：
2026-03-27
